$645 Million is the total value of MPM BioImpact LLC's 33 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 135.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Sell | Cullinan Oncology, Inc. | $172,621,000 | -15.3% | 7,648,268 | -3.4% | 26.78% | -20.0% |
| ITOS | Sell | iTeos Therapeutics, Inc. | $56,891,000 | -5.2% | 2,107,092 | -9.9% | 8.82% | -10.4% |
| RPTX | Sell | Repare Therapeutics, Inc. | $43,030,000 | -17.7% | 1,639,849 | -2.2% | 6.68% | -22.2% |
| HOWL | Werewolf Therapeutics, Inc. | $40,978,000 | -1.6% | 2,388,011 | 0.0% | 6.36% | -7.1% | |
| Buy | MEI Pharma, Inc. | $34,484,000 | +19.4% | 12,494,118 | +23.2% | 5.35% | +12.7% | |
| TCRR | TCR2 Therapeutics, Inc. | $28,687,000 | -48.1% | 3,370,982 | 0.0% | 4.45% | -51.0% | |
| HARP | Harpoon Therapeutics, Inc. | $25,254,000 | -43.0% | 3,196,707 | 0.0% | 3.92% | -46.2% | |
| ONCR | Oncorus, Inc. | $22,201,000 | -32.3% | 2,377,031 | 0.0% | 3.44% | -36.1% | |
| NTLA | New | Intellia Therapeutics, Inc. | $21,815,000 | – | 162,620 | +100.0% | 3.38% | – |
| MRUS | Buy | Merus N.V. | $20,723,000 | +40.3% | 941,948 | +34.4% | 3.21% | +32.5% |
| EPZM | Buy | Epizyme, Inc. | $20,341,000 | +5.0% | 3,972,830 | +70.4% | 3.16% | -0.9% |
| TPTX | Buy | Turning Point Therapeutics, Inc. | $18,026,000 | -14.2% | 271,350 | +0.8% | 2.80% | -19.0% |
| YMAB | Buy | YmAbs Therapeutics, Inc. | $12,928,000 | +13.4% | 452,970 | +34.3% | 2.00% | +7.0% |
| GTHX | Buy | G1 Therapeutics, Inc. | $11,548,000 | -35.2% | 860,502 | +5.9% | 1.79% | -38.9% |
| BCRX | New | Biocryst Pharmaceuticals Inc. | $10,128,000 | – | 704,767 | +100.0% | 1.57% | – |
| ADCT | Buy | ADC Therapeutics, Inc. | $9,357,000 | +76.2% | 344,519 | +58.0% | 1.45% | +66.4% |
| CYTK | New | Cytokinetics Inc. | $8,838,000 | – | 247,291 | +100.0% | 1.37% | – |
| VSTM | New | Verastem, Inc. | $8,701,000 | – | 2,824,857 | +100.0% | 1.35% | – |
| GERN | New | Geron Corporation | $7,854,000 | – | 5,732,770 | +100.0% | 1.22% | – |
| TVTX | New | Travere Therapeutics Inc. | $7,433,000 | – | 306,515 | +100.0% | 1.15% | – |
| NEO | New | Neogenomics Inc. | $7,212,000 | – | 149,504 | +100.0% | 1.12% | – |
| CRNX | New | Crinetics Pharmaceuticals Inc. | $6,281,000 | – | 298,392 | +100.0% | 0.97% | – |
| MIRM | New | Mirum Pharmaceuticals Inc. | $6,146,000 | – | 308,532 | +100.0% | 0.95% | – |
| HRMY | New | Harmony Biosciences Hldgs Inc. | $5,813,000 | – | 151,650 | +100.0% | 0.90% | – |
| EPIX | New | ESSA Pharma, Inc. | $5,466,000 | – | 683,287 | +100.0% | 0.85% | – |
| FOLD | New | Amicus Therapeutics Inc. | $5,220,000 | – | 546,558 | +100.0% | 0.81% | – |
| AVRO | New | AVROBIO, Inc. | $4,809,000 | – | 861,858 | +100.0% | 0.75% | – |
| LHDX | New | Lucira Health Inc. | $4,394,000 | – | 578,114 | +100.0% | 0.68% | – |
| RVMD | New | Revolution Medicines, Inc. | $4,127,000 | – | 150,000 | +100.0% | 0.64% | – |
| AVDL | New | Avadel Pharmaceuticals Plc | $3,920,000 | – | 400,000 | +100.0% | 0.61% | – |
| INZY | New | Inozyme Pharma Inc. | $3,717,000 | – | 320,724 | +100.0% | 0.58% | – |
| AXSM | New | Axsome Therapeutics Inc. | $3,631,000 | – | 110,155 | +100.0% | 0.56% | – |
| BDTX | New | Black Diamond Therapeutics, Inc. | $2,102,000 | – | 248,506 | +100.0% | 0.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.